BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22416063)

  • 1. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
    Oncologist; 2012; 17(4):512. PubMed ID: 22416063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
    Robey RW; Shukla S; Finley EM; Oldham RK; Barnett D; Ambudkar SV; Fojo T; Bates SE
    Biochem Pharmacol; 2008 Mar; 75(6):1302-12. PubMed ID: 18234154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
    Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
    Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
    Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
    Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
    Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
    Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
    Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
    Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
    Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
    Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
    Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi.
    Kabasakal L; Halaĉ M; Nisli C; Oguz O; Onsel C; Civi G; Uslu I
    Clin Nucl Med; 2000 Jan; 25(1):20-3. PubMed ID: 10634525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis.
    Harpstrite SE; Gu H; Natarajan R; Sharma V
    Nucl Med Commun; 2014 Oct; 35(10):1067-70. PubMed ID: 25036383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
    Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
    J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
    J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of resistance to paclitaxel of murine tumors by (99m)Tc-MIBI/(201)Tl dual-radionuclide imaging.
    Oriuchi N; Jibu T; Milas L; Choe J; Kuang L; Kim EE; Hunter NR; Wallace S; Podoloff DA
    Nucl Med Biol; 2000 Feb; 27(2):127-33. PubMed ID: 10773541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
    Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
    Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.
    van Leeuwen FW; Buckle T; Kersbergen A; Rottenberg S; Gilhuijs KG
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):406-12. PubMed ID: 19093112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
    Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
    J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?
    Yokogami K; Kawano H; Moriyama T; Uehara H; Sameshima T; Oku T; Goya T; Wakisaka S; Nagamachi S; Jinnouchi S; Tamura S
    Eur J Nucl Med; 1998 Apr; 25(4):401-9. PubMed ID: 9553170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma.
    Chang CS; Huang WT; Yang SS; Yeh HZ; Kao CH; Chen GH
    Nucl Med Biol; 2003 Feb; 30(2):111-7. PubMed ID: 12623109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.